ReviewThe Journal of international medical research2026
Advances in the management of gout: From current strategies to emerging therapies.
Review in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is a form of inflammatory arthritis caused by disordered uric acid metabolism, characterized by severe joint pain and inflammatory reactions, which significantly impair patients' quality of life. With changes in lifestyle and dietary habits, the incidence of gout has been rising globally, making it a critical public health concern. Current research primarily focuses on short- and long-term management strategies, including pharmacological therapies, lifestyle interventions, and patient education. Short-term management typically comprises nonsteroidal anti-inflammatory drugs and colchicine to alleviate acute attacks, while long-term management focuses on uric acid control and recurrence prevention through urate-lowering drugs. Although existing management strategies can effectively control symptoms, challenges such as poor patient adherence and insufficient individualized treatment persist. Emerging therapies, including biologics and gene-based treatments, have demonstrated promising potential and may offer more effective and personalized therapeutic solutions for patients with gout. This narrative review aims to provide a comprehensive synthesis of existing literature to inform clinical practice and explore future directions in gout management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.